Creekmur Asset Management LLC Buys Shares of 512 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Creekmur Asset Management LLC purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 512 shares of the company's stock, valued at approximately $215,000.

A number of other institutional investors have also recently modified their holdings of IDXX. MorganRosel Wealth Management LLC purchased a new stake in IDEXX Laboratories during the first quarter worth $26,000. Hurley Capital LLC purchased a new stake in IDEXX Laboratories during the fourth quarter worth $29,000. Colonial Trust Co SC boosted its position in IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after purchasing an additional 39 shares in the last quarter. Itau Unibanco Holding S.A. boosted its position in IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Cornerstone Planning Group LLC boosted its position in IDEXX Laboratories by 108.0% during the first quarter. Cornerstone Planning Group LLC now owns 104 shares of the company's stock worth $44,000 after purchasing an additional 54 shares in the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director directly owned 1,801 shares of the company's stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Price Performance

Shares of IDXX traded down $4.10 on Friday, hitting $514.61. The company's stock had a trading volume of 329,531 shares, compared to its average volume of 642,698. The company has a market capitalization of $41.38 billion, a PE ratio of 47.56, a PEG ratio of 3.74 and a beta of 1.54. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $549.52. The company has a 50 day moving average price of $523.58 and a 200 day moving average price of $463.04.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.93 by $0.03. The firm had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.71 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on IDXX shares. Stifel Nicolaus upped their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research note on Wednesday, July 2nd. Leerink Partners upped their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a research note on Thursday. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Morgan Stanley increased their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Finally, Jefferies Financial Group started coverage on IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $560.33.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.